Clinical Trials Browser

Uterine Cervical Diseases, Papillomavirus Infections

NCT06362421 2025-07-31

Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer

Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT04142398 2025-06-06

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Withdrawn

HIV Infections, Papillomavirus Infections

NCT00733122 2025-03-03

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Phase 3 Withdrawn

Papillomavirus Infections

NCT00501189 2024-06-11

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

Withdrawn

Papillomavirus Infections, Atypical Squamous Cells of the Cervix

NCT05316064 2024-05-10

Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic

Phase 2/3 Withdrawn

Papillomavirus Infections

NCT04430907 2021-07-02

HPV Vaccine in Postpartum Women

Withdrawn

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT04044950 2020-09-22

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Phase 2 Withdrawn

Head & Neck

Oropharyngeal Neoplasms, Papillomavirus Infections

NCT03887793 2020-02-26

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

Phase NA Withdrawn

Papillomavirus Infections

NCT02082639 2015-07-20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Phase 3 Withdrawn

Papillomavirus Infections

NCT02100618 2015-07-20

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Phase 3 Withdrawn

Papillomavirus Infections

NCT00736216 2015-03-19

Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

Withdrawn

GynecologicOther neoplasm

Uterine Cervical Neoplasms, Precancerous Conditions, Papillomavirus Infections

NCT01551537 2013-09-09

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Withdrawn

Papillomavirus Infections

Clinical Trials

HPV-RWS

Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic

HPV Vaccine in Postpartum Women

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka